Navigation Links
Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019
Date:9/28/2010

BURLINGTON, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to increasing generic availability of antihypertensive agents, the hypertension drug market will decline from $26 billion in 2009 to $23 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Hypertension reveal that the market-leading drug, Novartis's Diovan/Tareg, will suffer the greatest decline as its sales will decrease more than $1 billion in 2013, following the entry of generic versions of the drug. By 2019, the drug classes typically used as first-, second-, and third-line therapy will all be subject to generic competition — these drug classes are the angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRA), calcium channel blockers (CCBs) and diuretics.

"Emerging agents will find it difficult to penetrate the highly genericized hypertension market because of competition from inexpensive and efficacious generic antihypertensive drugs," said Decision Resources Analyst Taskin Ahmed. "Through 2019, we do not forecast blockbuster sales for any of the emerging antihypertensive agents."

The Pharmacor 2010 findings also reveal that, although the overall market will decline, sales of therapies offering greater convenience, such as fixed-dose combinations, will increase over the next several years. The CCB/ renin-angiotensin-aldosterone system (RAAS) inhibitor fixed-dose combinations and CCB/RAAS inhibitor/diuretic fixed-dose combinations will capitalize on this opportunity, generating approximately $6 billion in total sales in 2019.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
2. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
3. Hypertension Drug Market Will Experience Only Modest Annual Decline Through 2018, Despite Generic Erosion Of Many Branded Agents
4. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
5. GPhA Says BIO Cries Wolf on Senate Biogenerics Proposal
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
7. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
8. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
9. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... 24, 2015  Champions Oncology (OTC-BB: CSBR), a company ... services to personalize the development and use of oncology ... operational results for the fourth quarter and fiscal year ... 2015, before market open. The company will ... day at 9:00 a.m. EDT (6:00 a.m. PDT). To ...
(Date:7/24/2015)... , July 24, 2015 , ... , Expands product offering for chronic kidney disease ... needs in diabetes-related complications and dermatology , Increases ... (HKEX:1530) ("3SBio" or ,the Company"), a leading ... manufacturing and marketing biopharmaceutical products, today announced that it ...
(Date:7/23/2015)... ... , ... Science and technology continue to improve all aspects of brain tumor ... to Susan Chang, MD, director of the Division of Neuro-oncology at UC San Francisco. ... impacting the development of new treatments and advancing strategies to minimize treatment side effects ...
(Date:7/23/2015)... ... July 23, 2015 , ... The Pittcon 2016 Program Committee ... Mosher Professor of Chemistry and Professor, by courtesy, of Applied Physics at Stanford University, ... in Solids Led to Super-Resolution Nanoscopy in Cells and Beyond” , Dr. Moerner’s ...
Breaking Biology Technology:Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 23SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 2The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 3
... US - A team of Bioengineers in the United ... its ability to produce ethanol. The research, published in ... metabolic engineering can be combined for strain improvement, a ... focused their research on Zymomonas mobilis, a bacterium noted ...
... NEW YORK, Dec. 10, 2010 Ramius V&O Acquisition ... announced that it has sent a letter to the ... CYPB ) outlining its willingness to acquire all ... for $5.50 per share.  The offer is conditioned upon ...
... new hand-held medical device will help UK athletes reach ... sporting competitions. UK Sport, the UK,s high performance sports ... organisation to use cutting edge technology developed by Argento ... athletes will be able to monitor various proteins which ...
Cached Biology Technology:Bioengineers develop bacterial strain to increase ethanol biofuel production 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6Medical science helps UK athletes reach peak performance 2Medical science helps UK athletes reach peak performance 3
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... University Medical Center, Chicago, and Ceregene Inc., San Diego, ... and stop the anatomic, cellular changes that occur in ... is the first study to demonstrate that, using this ... mice with this treatment. , Results of the ...
... The Hospital for Sick Children (SickKids) and the University of ... can create neural cell types that can be transplanted into ... reported in the June 14, 2006 issue of The Journal ... of cells can be made from these stem cells (called ...
... that go on to form the face, skull and ... is determined much earlier in development than previously thought, ... according to a recent study published in the journal ... with three different technologies -- immunostaining of proteins, in ...
Cached Biology News:Gene therapy injected into the brains' of mice with Huntington's disease 2Gene therapy injected into the brains' of mice with Huntington's disease 3Gene therapy injected into the brains' of mice with Huntington's disease 4Stem cells found in adult skin can be transplanted and function in mouse models of disease 2Making a face: A new and earlier marker of neural crest development 2
NATIVE RAT OSTEOCALCIN...
... W x H): 17 3/4" x ... 12 slidesTime: Programmable 0 - 100 hoursControl: ... hybridization steps 40 user programmable protocols 3 ... temperature) Rapid temperature ramp-up from 37 - ...
Defender against cell death 1...
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
Biology Products: